Format

Send to

Choose Destination
Int Arch Allergy Immunol. 2020;181(2):94-102. doi: 10.1159/000503684. Epub 2019 Dec 20.

Accelerated Dose Escalation with Three Injections of an Aluminum Hydroxide-Adsorbed Allergoid Preparation of Six Grasses Is Safe for Patients with Moderate to Severe Allergic Rhinitis.

Author information

1
Department of Pediatric Pulmonology and Allergology, University of Lübeck, University Medical Center Schleswig-Holstein, Lübeck, Germany, matthias.kopp@uksh.de.
2
Airway Research Center North, Member of the German Center of Lung Research (DZL), Lübeck, Germany, matthias.kopp@uksh.de.
3
Department of Pediatric Pulmonology and Allergology, University of Lübeck, University Medical Center Schleswig-Holstein, Lübeck, Germany.
4
Airway Research Center North, Member of the German Center of Lung Research (DZL), Lübeck, Germany.
5
Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany.

Abstract

Only few data on safety during high-dose, accelerated escalation schedules during subcutaneous allergen immunotherapy (AIT) are available. The aim of this study was to assess the safety and tolerability of an accelerated dose escalation schedule of AIT in adult patients with moderate to severe seasonal rhinoconjunctivitis in a multicenter, open-label, randomized phase II trial. The dose escalation scheme for patients in Group I (1 strength) included 3 injections with 1 strength, B (10,000 TU/mL), whereas the dose escalation scheme for Group II (standard) included 7 injections with 2 strengths, A (1,000 TU/mL) and B (10,000 TU/mL), of an aluminum hydroxide-adsorbed allergoid grass pollen preparation. Overall, 72 of 87 randomized patients (83.7%) reported at least 1 treatment-emergent adverse event (TEAE; 82.2 [Group I] vs. 85.4% [Group II]); 58.8% of all reported TEAEs were assessed as being related to AIT (60.0 vs. 48.8%). The most frequently reported AIT-related TEAEs were swelling (46.7 vs. 34.1%), erythema (28.9 vs. 36.6%), and pruritus (31.1 vs. 17.1%) at the site of the injection. Systemic allergic reactions occurred in 5 (5.8%) patients overall, with more being reported in the 1-strength group (4 [8.9%] vs. 1 [2.4%]). All systemic allergic reactions were classified as World Allergy Organization (WAO) Grade 1 or Grade 2 reactions. Accelerated high-dose escalation with an aluminum hydroxide-adsorbed grass pollen allergoid can be initiated with a safety and tolerability profile comparable to the standard dose escalation schedule in patients with allergic rhinitis with or without asthma.

KEYWORDS:

Accelerated dose escalation; Allergen-specific immunotherapy; Allergic rhinitis; Allergoids; Side effects

PMID:
31865326
PMCID:
PMC7050673
DOI:
10.1159/000503684
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center